Drugs / E7 TCR cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02858310 | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7 TCR cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02858310 ↗ |
| Modality | Cell therapy | “T cells genetically engineered with a TCR targeting HPV-16 E7” NCT02858310 ↗ |